Core Viewpoint - MicroPort Scientific Corporation (微创机器人-B) reported significant revenue growth and reduced losses for the fiscal year ending December 31, 2025, indicating strong market performance and expansion potential in the surgical robotics sector [2] Financial Performance - The company achieved a revenue of 551 million RMB, representing a year-on-year increase of 114.2% [2] - The loss attributable to equity shareholders narrowed to 250 million RMB, a reduction of 61.1% compared to the previous year [2] - Basic loss per share was reported at 0.24 RMB [2] Product and Market Development - The revenue growth was primarily driven by the commercialization of the core product, the TiMeye surgical robot, which has seen breakthrough progress [2] - Sales growth was particularly strong in overseas markets, with over 100 new orders signed in international markets throughout the year [2] - Overseas market sales revenue increased to more than five times that of the previous year, significantly outpacing the industry average growth rate, showcasing robust global expansion momentum [2]